# Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

> **NCT02889848** · PHASE1 · COMPLETED · sponsor: **Advance Biofactures Corporation** · enrollment: 15 (actual)

## Conditions studied

- Fibroids, Uterine
- Leiomyoma

## Interventions

- **OTHER:** Saline
- **DRUG:** EN3835

## Key facts

- **NCT ID:** NCT02889848
- **Lead sponsor:** Advance Biofactures Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-27
- **Primary completion:** 2018-10-05
- **Final completion:** 2018-11-15
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02889848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02889848, "Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02889848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*